enGene (NASDAQ:ENGN – Get Free Report) is one of 671 public companies in the “Holding & other investment offices” industry, but how does it weigh in compared to its competitors? We will compare enGene to similar businesses based on the strength of its valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and profitability.
Volatility and Risk
enGene has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, enGene’s competitors have a beta of 0.04, indicating that their average share price is 96% less volatile than the S&P 500.
Valuation and Earnings
This table compares enGene and its competitors gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
enGene | N/A | $30,000.00 | -5.52 |
enGene Competitors | $964.75 million | $74.29 million | 46.88 |
Profitability
This table compares enGene and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
enGene | N/A | N/A | -5.65% |
enGene Competitors | -20.12% | -42.63% | -0.78% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for enGene and its competitors, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
enGene | 0 | 0 | 6 | 0 | 3.00 |
enGene Competitors | 127 | 572 | 871 | 15 | 2.49 |
enGene currently has a consensus price target of $34.40, indicating a potential upside of 282.22%. As a group, “Holding & other investment offices” companies have a potential upside of 49.09%. Given enGene’s stronger consensus rating and higher possible upside, equities analysts clearly believe enGene is more favorable than its competitors.
Insider and Institutional Ownership
64.2% of enGene shares are held by institutional investors. Comparatively, 54.0% of shares of all “Holding & other investment offices” companies are held by institutional investors. 13.7% of enGene shares are held by company insiders. Comparatively, 25.9% of shares of all “Holding & other investment offices” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
enGene competitors beat enGene on 7 of the 13 factors compared.
enGene Company Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.